Latest News

business partners
Cybin Announces Partnership With Osmind to Advance Clinical-Stage Psychiatry Programs

April 22nd 2025

Cybin partners with Osmind to enhance mental health treatment access, focusing on innovative therapies for depression and anxiety disorders.

clinical trial
MindMed Begins Phase 3 Emerge Study of MM120 in Patients With Major Depressive Disorder

April 21st 2025

Jesse H. Wright, MD, PhD
Reflections on 50 Years in Psychiatry: An Interview with Jesse H. Wright, MD, PhD

April 17th 2025

white lotus
Lorazepam and the White Lotus in our Tariff Times

April 8th 2025

Latest CME Events & Activities

Expert Perspectives in the Recognition and Management of Postpartum Depression

View More

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

Southern Florida Psychiatry Conference

November 21-22, 2025

Register Now!

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

View More

Optimizing Care for Patients With Tardive Dyskinesia

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

More News

© 2025 MJH Life Sciences

All rights reserved.